Ablitech to begin testing cancer treatment
HATTIESBURG — Ablitech’s CEO Ken Malone announced that the company is closer to advancing technology that has the ability to stop bladder cancer through its product Versadel.
Malone said, “The proof is in the lab; a place where we are seeing very promising ways of ending certain cancers and degenerative diseases as we know them today.”
“Our technology effectively carries the DNA to the cells and releases it, enabling the cells to function like they were always meant to,” chief science officer of Ablitech Dr. Lisa Kemp said.
Ablitech, which received a second round of funding under the Mississippi Seed Fund earlier this month, said it would next begin agenda–testing Versadel in animal models.
Kemp said, “At this point we are limited to what we can do in the lab working with cells to prove that our science works. It is imperative to move our product to the living system to see our theories in action.”
Ablitech is collaborating with professors and Tulane Cancer Center who have an established animal model. Until the models begin, they continue to focus their efforts on purification and optimization in preparation of the study.
To sign up for Mississippi Business Daily Updates, click here.
Twang & Tourism: The Country Music Trail
Still planning that summer vacation?
FOLLOW THE MBJ ON TWITTERMy Tweets
Top Posts & Pages
- Silver Airways ordered to continue service
- Seafood R’evolution set to make Mississippi ‘the new culinary epicenter of the South’
- Bryant signs controversial abortion ban bill
- Soybean yield more than doubles in less than a decade
- Two Delta groups getting economic development funding
- Pharma Pac lays off rest of workers; could end up owing state
- Plans unveiled for large shooting range on Coast
- Ole Miss launches commitment to be 'climate neutral'
- Yarber could be sworn in today as new Jackson mayor
- Biloxi baseball project still alive but may be held for 2015